HK1123295A1 - Pyrazolone derivatives as 11-beta hsd1 inhibitors - Google Patents
Pyrazolone derivatives as 11-beta hsd1 inhibitorsInfo
- Publication number
- HK1123295A1 HK1123295A1 HK09100950.9A HK09100950A HK1123295A1 HK 1123295 A1 HK1123295 A1 HK 1123295A1 HK 09100950 A HK09100950 A HK 09100950A HK 1123295 A1 HK1123295 A1 HK 1123295A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrazolone derivatives
- hsd1 inhibitors
- beta hsd1
- beta
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107970 | 2005-08-31 | ||
PCT/EP2006/065471 WO2007025880A2 (en) | 2005-08-31 | 2006-08-21 | Pyrazolone derivatives as 11-beta hsd1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1123295A1 true HK1123295A1 (en) | 2009-06-12 |
Family
ID=37729936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09100950.9A HK1123295A1 (en) | 2005-08-31 | 2009-02-03 | Pyrazolone derivatives as 11-beta hsd1 inhibitors |
Country Status (23)
Country | Link |
---|---|
US (1) | US7652057B2 (en) |
EP (1) | EP1924562A2 (en) |
JP (1) | JP5073664B2 (en) |
KR (1) | KR100982088B1 (en) |
CN (1) | CN101243050B (en) |
AR (1) | AR055145A1 (en) |
AU (1) | AU2006286646B2 (en) |
BR (1) | BRPI0615039A2 (en) |
CA (1) | CA2618840C (en) |
CR (1) | CR9703A (en) |
EC (1) | ECSP088229A (en) |
HK (1) | HK1123295A1 (en) |
IL (1) | IL189186A0 (en) |
MA (1) | MA29775B1 (en) |
MX (1) | MX2008002583A (en) |
MY (1) | MY145464A (en) |
NO (1) | NO20080554L (en) |
NZ (1) | NZ565536A (en) |
RU (1) | RU2407737C2 (en) |
TW (1) | TWI332949B (en) |
UA (1) | UA90742C2 (en) |
WO (1) | WO2007025880A2 (en) |
ZA (1) | ZA200801444B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2367798B1 (en) * | 2008-11-20 | 2018-02-28 | Northwestern University | Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis |
US9428467B2 (en) | 2008-11-20 | 2016-08-30 | Northwestern University | Selective calcium channel antagonists |
US9145424B2 (en) | 2008-11-20 | 2015-09-29 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
SG2014014328A (en) | 2009-05-22 | 2014-07-30 | Abbvie Inc | Modulators of 5-ht receptors and methods of use thereof |
WO2011051958A1 (en) | 2009-10-30 | 2011-05-05 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazolones |
MX339840B (en) * | 2010-05-21 | 2016-06-14 | Abbvie Inc * | Modulators of 5-ht receptors and methods of use thereof. |
EP2881387A1 (en) | 2013-12-09 | 2015-06-10 | Basf Se | Pyrazolone compounds having herbicidal activity |
EP2881388A1 (en) | 2013-12-09 | 2015-06-10 | Basf Se | Pyrazolone compounds having herbicidal activity |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
WO2019048988A1 (en) | 2017-09-08 | 2019-03-14 | Pi Industries Ltd. | Novel fungidal heterocyclic compounds |
BR112020004356A2 (en) | 2017-09-08 | 2020-12-01 | Pi Industries Ltd. | new fungicidal heterocyclic compounds |
AU2019440945B2 (en) * | 2019-04-17 | 2024-06-06 | Pontificia Universidad Católica De Chile | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11Β-HSD1) |
CN113527207B (en) * | 2020-04-22 | 2023-06-06 | 常州强力电子新材料股份有限公司 | Ethoxy/propoxy modified pyrazoline organic matter, application thereof, photo-curing composition and photoresist |
CN112375072B (en) * | 2020-09-28 | 2021-05-28 | 上海长征富民金山制药有限公司 | Pyrazolone derivative, injection and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2731473A (en) * | 1956-01-17 | New pyrazolone derivatives | ||
DE668628C (en) | 1935-12-08 | 1938-12-07 | Beiersdorf & Co A G P | Process for the preparation of alkyl and aralkyl compounds of 3,4-cyclotetramethylene-1-aryl-5-pyrazolones |
JPS609752B2 (en) | 1979-11-09 | 1985-03-12 | 東邦新薬株式会社 | Novel 2-acetoxybenzamide derivative, its production method, and pharmaceuticals containing it as an active ingredient |
DE4415484A1 (en) | 1994-05-03 | 1995-11-09 | Basf Ag | Process for the preparation of 1- (het) aryl-3-hydroxy-pyrazoles |
US5663365A (en) | 1996-10-29 | 1997-09-02 | Japan Hydrazine Co., Ltd. | Process for the preparation of pyrazolones |
PT870757E (en) | 1997-04-10 | 2002-09-30 | Pfizer | ADAMANTAN DERIVATIVES SUBSTITUTED BY FLUORO |
TW536387B (en) | 1998-04-23 | 2003-06-11 | Sumitomo Chemical Co | Pyrazolinone compound |
KR100591585B1 (en) * | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
CZ305971B6 (en) * | 2000-12-28 | 2016-06-01 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicaments |
AU2003262023A1 (en) * | 2002-09-10 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
JP4486505B2 (en) | 2002-12-19 | 2010-06-23 | ブリストル−マイヤーズ スクイブ カンパニー | Substituted tricyclic gamma-carboline compounds as serotonin receptor agonists and antagonists |
GB0306718D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
JP2007501789A (en) * | 2003-08-07 | 2007-02-01 | メルク エンド カムパニー インコーポレーテッド | Pyrazole carboxamides as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 |
-
2006
- 2006-08-21 AU AU2006286646A patent/AU2006286646B2/en not_active Ceased
- 2006-08-21 BR BRPI0615039-0A patent/BRPI0615039A2/en not_active IP Right Cessation
- 2006-08-21 UA UAA200803780A patent/UA90742C2/en unknown
- 2006-08-21 CA CA2618840A patent/CA2618840C/en not_active Expired - Fee Related
- 2006-08-21 MY MYPI20080416A patent/MY145464A/en unknown
- 2006-08-21 CN CN2006800305234A patent/CN101243050B/en not_active Expired - Fee Related
- 2006-08-21 NZ NZ565536A patent/NZ565536A/en not_active IP Right Cessation
- 2006-08-21 JP JP2008528461A patent/JP5073664B2/en not_active Expired - Fee Related
- 2006-08-21 MX MX2008002583A patent/MX2008002583A/en active IP Right Grant
- 2006-08-21 KR KR1020087004807A patent/KR100982088B1/en not_active IP Right Cessation
- 2006-08-21 RU RU2008111971/04A patent/RU2407737C2/en not_active IP Right Cessation
- 2006-08-21 WO PCT/EP2006/065471 patent/WO2007025880A2/en active Application Filing
- 2006-08-21 EP EP06792909A patent/EP1924562A2/en not_active Withdrawn
- 2006-08-29 TW TW095131856A patent/TWI332949B/en not_active IP Right Cessation
- 2006-08-29 AR ARP060103758A patent/AR055145A1/en unknown
- 2006-08-29 US US11/511,542 patent/US7652057B2/en not_active Expired - Fee Related
-
2008
- 2008-01-29 CR CR9703A patent/CR9703A/en not_active Application Discontinuation
- 2008-01-30 NO NO20080554A patent/NO20080554L/en not_active Application Discontinuation
- 2008-02-03 IL IL189186A patent/IL189186A0/en unknown
- 2008-02-12 ZA ZA200801444A patent/ZA200801444B/en unknown
- 2008-02-27 EC EC2008008229A patent/ECSP088229A/en unknown
- 2008-03-14 MA MA30744A patent/MA29775B1/en unknown
-
2009
- 2009-02-03 HK HK09100950.9A patent/HK1123295A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AR055145A1 (en) | 2007-08-08 |
UA90742C2 (en) | 2010-05-25 |
WO2007025880A3 (en) | 2007-05-03 |
US7652057B2 (en) | 2010-01-26 |
CA2618840C (en) | 2011-07-05 |
CR9703A (en) | 2008-02-20 |
KR100982088B1 (en) | 2010-09-13 |
MA29775B1 (en) | 2008-09-01 |
ECSP088229A (en) | 2008-03-26 |
JP5073664B2 (en) | 2012-11-14 |
BRPI0615039A2 (en) | 2011-04-26 |
MY145464A (en) | 2012-02-15 |
MX2008002583A (en) | 2008-03-18 |
KR20080031482A (en) | 2008-04-08 |
CA2618840A1 (en) | 2007-03-08 |
TWI332949B (en) | 2010-11-11 |
AU2006286646A1 (en) | 2007-03-08 |
IL189186A0 (en) | 2008-06-05 |
JP2009506089A (en) | 2009-02-12 |
RU2407737C2 (en) | 2010-12-27 |
NO20080554L (en) | 2008-03-14 |
WO2007025880A2 (en) | 2007-03-08 |
EP1924562A2 (en) | 2008-05-28 |
RU2008111971A (en) | 2009-10-10 |
NZ565536A (en) | 2011-03-31 |
TW200740764A (en) | 2007-11-01 |
AU2006286646B2 (en) | 2010-09-23 |
ZA200801444B (en) | 2008-12-31 |
US20070049574A1 (en) | 2007-03-01 |
CN101243050A (en) | 2008-08-13 |
CN101243050B (en) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200801444B (en) | Pyrazolone derivatives as 11-Beta HSD1 inhibitors | |
IL193157A0 (en) | 11-beta hsd1 inhibitors | |
IL189048A (en) | Urea derivatives as gsk-3 inhibitors | |
TWI370127B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
IL190450A0 (en) | Substituted pyrazole compounds | |
IL198247A0 (en) | Indazole derivatives useful as l-cpt1 inhibitors | |
ATE517886T1 (en) | PYRAZOLE DERIVATIVES | |
EP1847531A4 (en) | Pyrazole compound | |
ZA200806148B (en) | 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors | |
IL198231A0 (en) | Pyridine carboxamides as 11??hsd1 inhibitors | |
IL189383A0 (en) | Derivatives of 4-piperazin-1-yl | |
IL200047A0 (en) | Pyrazole derivatives as 11-beta-hsd1 inhibitors | |
EP1948193A4 (en) | Aminopyrimidines useful as kinase inhibitors | |
EP1940843A4 (en) | Unsaturated heterocyclic derivatives | |
ZA200901127B (en) | Aminoindazole urea derivatives | |
IL180044A0 (en) | Pyrazole derivatives | |
HK1191574A1 (en) | Pyrazolone derivatives as pde4 inhibitors pde4 | |
HK1112918A1 (en) | Benzofuranyl derivatives as 5-ht6-receptor inhibitors | |
IL180889A0 (en) | Pyrazole derivative | |
ZA200800672B (en) | Introcatechol derivatives as COMT inhibitors | |
ZA200802786B (en) | Substituted pyrazole compounds | |
ZA200905235B (en) | Pyrazole derivatives as 11-beta-hsd1 inhibitors | |
ZA200804599B (en) | Aminopyrimidines useful as kinase inhibitors | |
ZA200706212B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
ZA200803288B (en) | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160821 |